Business Context and Reporting Period
Company: Phase III Medical, Inc. (formerly Corniche Group Incorporated; trading symbol PHSM).
Reporting Period: Fiscal year ended December 31, 2004.
Business Model: The Company provides capital and guidance to healthcare and life science companies in exchange for revenue percentages, royalties, and licensing fees. Its legacy business involves the "run-off" of extended warranty and service contracts sold via the Internet (WarrantySuperstore.com), which was discontinued in June 2002.
Key Financial Metrics (Year Ended Dec 31, 2004)
| Metric | 2004 Value | 2003 Value |
|---|---|---|
| Revenue | $48,561 | $64,632 |
| Gross Profit | $14,676 | $21,024 |
| Operating Loss | $(1,474,288) | $(894,329) |
| Net Loss (Attributable to Common) | $(1,748,372) | $(1,067,987) |
| Cash Balance (End of Period) | $27,868 | $210,947 |
| Working Capital Deficiency | $(1,238,949) | $(793,749) |
| Total Stockholders' Deficit | $(1,931,787) | $(1,502,774) |
| Notes Payable (Current) | $475,000 | $400,000 |
Note: Revenue is derived entirely from the run-off of prior warranty contracts. The Company has no cash-generating revenues from its new medical/biotech ventures.
Material Changes vs. Prior Period
- Increased Losses: Net loss increased by approximately 64% to $1.75 million, driven by higher operating expenses and interest costs.
- Expense Growth: General and administrative expenses rose 11.5% to $763,640, primarily due to increased salaries, insurance, and investor relations costs.
- Royalty Investment: The Company paid $725,324 to Parallel Solutions, Inc. (PSI) for a royalty interest in bioshielding technology, compared to $80,000 in 2003.
- Interest Expense: Interest expense increased to $226,599 (up from $214,897) due to higher debt levels and default penalties on certain notes.
- Cash Burn: Cash used in operating activities increased to $1.46 million from $1.02 million in the prior year.
Outlook, Risks, and Contingencies
- Going Concern: Auditors (Holtz Rubenstein Reminick LLP) have issued a modified opinion expressing substantial doubt about the Company's ability to continue as a going concern due to recurring losses and negative working capital.
- Liquidity Crisis: With only $27,868 in cash and a working capital deficit of $1.24 million, the Company requires immediate additional financing to fund operations and contractual obligations.
- Financing Efforts: An equity private placement intended to raise up to $4 million was terminated in July 2004 after raising only $1.32 million. The Company is currently funding operations through high-interest promissory notes (8% to 20%).
- Business Risks: The new medical/biotech strategy relies on partnerships (e.g., PSI, NeoStem) that are in early development stages with no assurance of profitability or regulatory approval. The Company has only two business partners to date.
- Contractual Obligations: Total contractual obligations as of Dec 31, 2004, were approximately $1.93 million, including $475,000 in notes payable and $668,340 in employment agreements.
Investor Verification Checklist
- Cash Runway: Verify current cash balance and immediate ability to meet payroll and debt service given the $27,868 balance reported.
- Debt Covenants: Review terms of outstanding notes payable, specifically those with default penalties and high interest rates (up to 20%).
- Preferred Stock: Assess the impact of 681,174 shares of Series A Preferred Stock, which are mandatorily redeemable and carry accrued dividends of $480,880.
- Partnership Viability: Evaluate the progress of the PSI bioshielding proof-of-concept study and the status of the NeoStem joint venture.
- Dilution Risk: Monitor potential dilution from outstanding options (6.675 million shares) and warrants, as well as future equity issuances required for survival.